149 related articles for article (PubMed ID: 34307175)
1. Case Report: The First Report of
Wang HP; He JJ; Zhu QY; Wang L; Li JH; Huang JS; Xie WZ; Zhu HH; Jin J
Front Oncol; 2021; 11():706798. PubMed ID: 34307175
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic
Stukaite-Ruibiene E; Norvilas R; Dirse V; Stankeviciene S; Vaitkeviciene GE
Pathol Oncol Res; 2022; 28():1610570. PubMed ID: 36172171
[TBL] [Abstract][Full Text] [Related]
3. NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.
De Keersmaecker K; Porcu M; Cox L; Girardi T; Vandepoel R; de Beeck JO; Gielen O; Mentens N; Bennett KL; Hantschel O
Haematologica; 2014 Jan; 99(1):85-93. PubMed ID: 23872305
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib and chemotherapy in a patient with early T-cell precursor acute lymphoblastic leukemia and
Chen Y; Zhang L; Huang J; Hong X; Zhao J; Wang Z; Zhang K
Exp Ther Med; 2017 Nov; 14(5):3979-3984. PubMed ID: 29067094
[TBL] [Abstract][Full Text] [Related]
5. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.
Graux C; Cools J; Melotte C; Quentmeier H; Ferrando A; Levine R; Vermeesch JR; Stul M; Dutta B; Boeckx N; Bosly A; Heimann P; Uyttebroeck A; Mentens N; Somers R; MacLeod RA; Drexler HG; Look AT; Gilliland DG; Michaux L; Vandenberghe P; Wlodarska I; Marynen P; Hagemeijer A
Nat Genet; 2004 Oct; 36(10):1084-9. PubMed ID: 15361874
[TBL] [Abstract][Full Text] [Related]
6. Clinico-Hematological Profile and Copy Number Abnormalities in a Cohort of
Patra N; Singh M; Sharma P; Trehan A; Naseem S; Bansal D; Bhatia P
Indian J Hematol Blood Transfus; 2021 Oct; 37(4):555-562. PubMed ID: 34744339
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
[TBL] [Abstract][Full Text] [Related]
8.
Choi YJ; Min YK; Lee ST; Choi JR; Shin S
Ann Lab Med; 2024 Jul; 44(4):335-342. PubMed ID: 38145892
[TBL] [Abstract][Full Text] [Related]
9. ABL1 fusions in T-cell acute lymphoblastic leukemia.
De Keersmaecker K
Verh K Acad Geneeskd Belg; 2008; 70(4):245-55. PubMed ID: 19166098
[TBL] [Abstract][Full Text] [Related]
10. Detection of a cryptic
Peterson JF; Pitel BA; Smoley SA; Smadbeck JB; Johnson SH; Vasmatzis G; Koon SJ; Webley MR; McGrath M; Bayerl MG; Baughn LB; Rowsey RA; Ketterling RP; Greipp PT; Hoppman NL
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30936193
[TBL] [Abstract][Full Text] [Related]
11.
Zhou MH; Yang QM
Oncol Lett; 2014 Sep; 8(3):959-962. PubMed ID: 25120641
[TBL] [Abstract][Full Text] [Related]
12. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
Quintás-Cardama A; Tong W; Manshouri T; Vega F; Lennon PA; Cools J; Gilliland DG; Lee F; Cortes J; Kantarjian H; Garcia-Manero G
Leukemia; 2008 Jun; 22(6):1117-24. PubMed ID: 18401417
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy.
Nardi V; McAfee SL; Dal Cin P; Tsai HK; Amrein PC; Hobbs GS; Brunner AM; Narayan R; Foster J; Fathi AT; Hock H
Oncologist; 2022 Mar; 27(2):82-86. PubMed ID: 35641210
[TBL] [Abstract][Full Text] [Related]
14. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
[TBL] [Abstract][Full Text] [Related]
15. NUP214-ABL1 in adult T-ALL: the GMALL study group experience.
Burmeister T; Gökbuget N; Reinhardt R; Rieder H; Hoelzer D; Schwartz S
Blood; 2006 Nov; 108(10):3556-9. PubMed ID: 16873673
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.
De Keersmaecker K; Versele M; Cools J; Superti-Furga G; Hantschel O
Leukemia; 2008 Dec; 22(12):2208-16. PubMed ID: 18784740
[TBL] [Abstract][Full Text] [Related]
17. Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion.
Blackburn PR; Huang L; Dalovisio A; Pitel BA; Chen D; Oliveira JL; Wood AJ; Smadbeck JB; Johnson SH; Vasmatzis G; Haferlach C; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Peterson JF
Cancer Genet; 2020 Feb; 241():67-71. PubMed ID: 31902694
[TBL] [Abstract][Full Text] [Related]
18. Blast phase of chronic myeloid leukemia with concurrent BCR::ABL1 and SET::NUP214: A report of two cases.
Chen Y; Wang Q; Cen J; Xu C; Tao TT; Xie J; Shen W; Gong Y; Pan J; Yao L
Mol Carcinog; 2023 Feb; 62(2):117-121. PubMed ID: 36321418
[TBL] [Abstract][Full Text] [Related]
19. The characteristics and prognostic significance of the SET-CAN/NUP214 fusion gene in hematological malignancies: A systematic review.
Wang J; Zhan QR; Lu XX; Zhang LJ; Wang XX; Zhang HY
Medicine (Baltimore); 2022 Jul; 101(30):e29294. PubMed ID: 35905214
[TBL] [Abstract][Full Text] [Related]
20. SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines.
Quentmeier H; Schneider B; Röhrs S; Romani J; Zaborski M; Macleod RA; Drexler HG
J Hematol Oncol; 2009 Jan; 2():3. PubMed ID: 19166587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
